A fluorogenic hypoxia-activated prodrug strategy for targeted compound delivery and imaging of tumours
<p>Hypoxia, a common feature in solid tumours, is associated with aggressive phenotypes, decreased genomic stability, and with increased resistance to all forms of cancer therapy. The significant differences between the hypoxic microenvironment, and normal tissues, present a therapeutic opport...
Main Author: | O'Connor, L |
---|---|
Other Authors: | Conway, S |
Format: | Thesis |
Published: |
2016
|
Similar Items
-
Fluorogenic platinum(iv) complexes as potential predictors for the design of hypoxia-activated platinum(iv) prodrugs
by: Marsh, J, et al.
Published: (2024) -
Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs
by: O'Connor, L, et al.
Published: (2016) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
by: Yue Li, et al.
Published: (2021-07-01) -
CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A.
by: Cazares-Körner, C, et al.
Published: (2013) -
Controlled sequential in situ self-assembly and disassembly of a fluorogenic cisplatin prodrug for cancer theranostics
by: Xidan Wen, et al.
Published: (2023-02-01)